The Nucleic Acid Core Facility is located in the Department of Gastrointestinal Oncology and Digestive Diseases in a 500 feet/2 laboratory. The Facility was created in the fall of 1996 through a CCSG supplement in Human Cancer Genetics. The NACF is a centralized facility for extraction of high-quality DNA from peripheral blood leukocytes and cell lines by using an Applied Biosystems Model 341 Nucleic Acid Extractor. This allows for the rapid isolation of highly purified, high- molecular-weight DNA. M.D. Anderson Cancer Center has a wealth of patient and family resources for studies of cancer-susceptibility genes. Most DNA isolation techniques used by individual laboratories required significant technical support and take 3 or more days. A centralized automated facility capable of producing PCR-grade DNA overnight from peripheral blood or cell is a major improvement in efficiency. The facility will be expanded to provide PCR-based genetic testing of transgenic animals. Because the high degree of product purity provided by the Model 341 Nucleic Acid Extractor will not be necessary for this testing, a more crude but rapid extraction procedure will be used to isolate DNA from mouse tails. The DNA will be subjected to PCR by using primates specifically designed to detect the transgenes, and animals positive for the transgenes will be identified. A large number of transgenic animal lines from over 20 different laboratories at M.D. Anderson are currently under investigation. Conducting DNA extraction from transgenic animal tails and PCR-based genetic testing in one centralized facility will be more efficient than performing these tasks in individual laboratories, as it will allow automation of each step by the use of Beckman Biomek 2000 robotic arms and multiplex PCR.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-25S2
Application #
6352707
Study Section
Project Start
2000-07-18
Project End
2001-06-30
Budget Start
Budget End
Support Year
25
Fiscal Year
2000
Total Cost
$254,104
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Taylor, Alison M; Shih, Juliann; Ha, Gavin et al. (2018) Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell 33:676-689.e3
Golemis, Erica A; Scheet, Paul; Beck, Tim N et al. (2018) Molecular mechanisms of the preventable causes of cancer in the United States. Genes Dev 32:868-902
Jabbour, Elias; DerSarkissian, Maral; Duh, Mei Sheng et al. (2018) Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 18:257-265
Pataer, Apar; Shao, Ruping; Correa, Arlene M et al. (2018) Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy. Cancer Med 7:2405-2414
Short, Nicholas J; Kantarjian, Hagop; Ravandi, Farhad et al. (2018) A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 59:813-820
Shank, Brandon R; Deaver, Melissa; Baker, Angela et al. (2018) Interdisciplinary implementation of tacrolimus intravenous standard concentration in hematopoietic stem cell transplantation recipients. J Oncol Pharm Pract 24:365-370
Keung, Emily Z; Chiang, Yi-Ju; Voss, Rachel K et al. (2018) Defining the incidence and clinical significance of lymph node metastasis in soft tissue sarcoma. Eur J Surg Oncol 44:170-177
Wang, Jue; Zhao, Wei; Guo, Huifang et al. (2018) AKT isoform-specific expression and activation across cancer lineages. BMC Cancer 18:742
Lu, Zhongming; Sturgis, Erich M; Zhu, Lijun et al. (2018) Mouse double minute 4 variants modify susceptibility to risk of recurrence in patients with squamous cell carcinoma of the oropharynx. Mol Carcinog 57:361-369
Murray, Thomas A; Yuan, Ying; Thall, Peter F et al. (2018) A utility-based design for randomized comparative trials with ordinal outcomes and prognostic subgroups. Biometrics 74:1095-1103

Showing the most recent 10 out of 12418 publications